Shenzhen Glory Medical (002551.SZ): Repurchase completed, a total of 2,999.47 million yuan was spent to repurchase 1,030,300 shares.
Shenzhen Glory Medical (002551.SZ) announced on June 7 that the deadline for the company's share buyback has expired as of the disclosure date of the announcement. As of the disclosure date of this announcement, the company has cumulatively repurchased 1,030,300 shares of the company's stock through the special securities account for repurchases in a centralized competitive bidding manner, accounting for 0.12% of the company's total share capital. The highest fill price was 3.10 yuan/share and the lowest fill price was 2.57 yuan/share, with a total amount paid of 2.99947 million yuan (excluding transaction fees).
Shang Rong Healthcare: No downward revisions to the “Shang Rong Bonds” conversion price
Shenzhen Shangrong Medical Co., Ltd. issued an announcement. As of May 24, 2024, the company's stock had triggered a downward revision of the “Shangrong Bonds” conversion price, but the board of directors decided not to revise the share conversion price downward this time, and will not propose a correction plan within the next six months.
Shangrong Convertible Bonds: Expected to trigger downward correction conditions for share conversion prices
Shenzhen Shangrong Medical Co., Ltd. announced that from May 1, 2024, as of May 17, 2024, the closing price of the company's stock was lower than 90% of the current share conversion price for 10 consecutive trading days, which is expected to trigger downward correction conditions for the “Shangrong Bonds” conversion price.
Shangrong Medical (002551.SZ): Initial repurchase of 400,000 shares
Gelonghui, May 10, 丨 Shangrong Medical (002551.SZ) announced that on May 10, 2024, for the first time, the company repurchased 400,000 shares of the company's shares through a special stock repurchase securities account, accounting for 0.05% of the company's current total share capital (based on the company's total share capital as of May 9, 2024). The maximum transaction price was 3.10 yuan/share, and the minimum transaction price was 3.08 yuan/share. The total transaction amount was 1,236,000.00 yuan (excluding transaction fees).
The China Securities Convertible Index opened down 0.02%. Among them, Shang Rong Convertible, Polaroid, Hangxin Convertible, Baichuan Transfer 2, and Jin Dan Convertible had the highest declines, falling 3.09%, 1.82%, 1.64%, 1.26%, and 1.1%, respectively.
The China Securities Convertible Index opened down 0.02%. Among them, Shang Rong Convertible, Polaroid, Hangxin Convertible, Baichuan Transfer 2, and Jin Dan Convertible had the highest declines, falling 3.09%, 1.82%, 1.64%, 1.26%, and 1.1%, respectively. In terms of growth, Kaineng Convertible Bonds, Tailin Convertible Bonds, Nootai Convertible Bonds, Mingdian Convertible Bonds, and Mingdian Transfer 02 had the highest gains, rising 13.74%, 10.38%, 1.15%, 1.1%, and 1.07%, respectively.
The medical device sector boosted Paulette's rise and stopped
Glonghui, May 7 | Paulette and Shangrong Medical rose and stopped, while Libang Instruments, Shanwaishan, Dongfulong, and Hong Kong Express Healthcare quickly followed suit. According to the news, the Health and Health Commission and eight other departments jointly issued “Opinions on Strengthening Capacity Building for Intensive Medicine Medical Services” on May 6. The opinion suggests that by the end of 2025, the number of intensive care beds nationwide will reach 15 beds/100,000 people, and the ratio of comprehensive ICU beds in relevant medical institutions will reach 1:0.8, and the bed care ratio will reach 1:3.
The China Securities Transfer Index opened up 0.03%; Baichuan Transfer 2 rose more than 8%; Jin Dan and Shang Rong Convertible Bonds rose more than 6%; China Securities Transfer 2 fell more than 2%, and Gold Stock Transfer fell more than 1%.
The China Securities Transfer Index opened up 0.03%; Baichuan Transfer 2 rose more than 8%; Jin Dan and Shang Rong Convertible Bonds rose more than 6%; China Securities Transfer 2 fell more than 2%, and Gold Stock Transfer fell more than 1%.
Shangrong Medical (002551.SZ) reported first-quarter results, net profit of 13.8835 million yuan, an increase of 97.44% over the previous year
According to Zhitong Finance App, Shang Rong Healthcare (002551.SZ) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 276 million yuan, a year-on-year decrease of 10.75%; net profit attributable to shareholders of listed companies was 13.8835 million yuan, an increase of 97.44% year on year; net profit attributable to shareholders of listed companies deducted 63.35 million yuan per share without recurring profit and loss, an increase of 3.80%; basic earnings per share were 0.02 yuan/share.
Shangrong Medical (002551.SZ) reported 2023 results, with a net loss of 149 million yuan, a year-on-year decrease of 51.67%
Shangrong Medical (002551.SZ) released its 2023 annual report, with revenue of 1,193 billion yuan, compared with...
Express News | More than 20 listed companies announced plans to repurchase or increase their holdings today, and Shanxi Fenjiu plans to increase their holdings by up to 200 million yuan
Shangrong Medical (002551.SZ) plans to buy back A shares no more than 8.58 million yuan
Gelonghui, March 10 | Shangrong Medical (002551.SZ) announced that in view of recent large fluctuations in the company's stock price, based on confidence in the company's future sustainable development and reasonable judgment on the company's long-term value, in order to effectively protect the interests of shareholders, enhance investor confidence, and comprehensively consider business development prospects, the company plans to raise its own funds to buy back some of the company's A-shares through centralized bidding to protect the company's value and shareholders' rights. The total capital of this repurchase is not more than RMB 8.58 million, and the price of the shares repurchased is no more than RMB 4.29 per share.
Shang Rong Medical (002551.SZ): Pre-loss of 100 million yuan to 150 million yuan in 2023
Gelonghui, January 26 | Shangrong Medical (002551.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 10 million yuan to 150 million yuan, an increase of 67.54% — 51.31% over the same period last year; net profit loss after deducting non-recurring profit and loss was 105.1749 million yuan to 155.1749 million yuan, an increase of 67.63% — 52.25% over the same period last year; basic earnings loss per share was 0.118 yuan/share — 0.178 yuan/share. During the reporting period, the company's holding subsidiary Hefei Pulder Medical Products Co., Ltd.
Shangrong Medical (002551.SZ) and related parties accepted the Shenzhen Regulatory Bureau's decision on administrative supervision measures
Shang Rong Medical (002551.SZ) issued an announcement. The company and related parties will accept it on November 27, 2023...
Shang Rong Healthcare (002551.SZ): No downward revision of the “Shang Rong to Debt” conversion price
Glonghui on October 31 | Shang Rong Medical (002551.SZ) announced that as of October 31, 2023, the closing price of Shenzhen Shangrong Medical Co., Ltd. stock has been lower than 90% of the current stock conversion price for at least 15 out of 30 consecutive trading days, which has triggered a downward revision clause on the “Shang Rong to Bonds” conversion price. After the 15th interim meeting of the 7th board of directors of the company deliberated and passed the “Proposal on not revising the conversion price of Shang Rong to Bonds” downward, the board of directors of the company decided not to exercise a downward revision of the stock conversion price at this time. Furthermore, within the next six months (i.e. 2023
Shangrong Medical (002551.SZ) released the first three quarter results, net profit of 135.151,000 yuan, an increase of 130.11%
Shangrong Medical (002551.SZ) released its report for the third quarter of 2023. The company's revenue for the first three quarters was 9...
Shang Rong Medical (002551.SZ): Net profit of 1.5531 million yuan in the first half of the year reversed losses year-on-year
Glonghui, August 28丨Shang Rong Medical (002551.SZ) announced its 2023 semi-annual report. Operating income for the reporting period was 600 million yuan, down 4.40% from the previous year; net profit attributable to shareholders of listed companies was 1,15531 million yuan, turning a loss into a profit; net profit attributable to shareholders of listed companies was 6.6574 million yuan after deducting non-recurring profit and loss; basic earnings per share of 0.01 yuan.
Shang Rong Healthcare (002551.SZ): Subsidiary assets will be auctioned
Glonway, July 13丨Shang Rong Medical (002551.SZ) announced that the company recently learned through an inquiry that the liquidation assets of the Qinhuangdao Guangji Hospital Management Co., Ltd. (known as “Guangji Hospital Management Company”) project invested by the company were publicly auctioned on the China Auction Platform. It was commissioned that Hebei Shibang Auction Co., Ltd. will start at 09:30 on August 10, 2023 on the east side of Qiancheng Wucheng Street, on the east side of the Haihai Expressway in Beidaihebin New Area. One land use right south of Rokujai and what is on that parcel of land Construction projects. Starting price: 11
Shang Rong Healthcare (002551.SZ): Preliminary profit of 8 million yuan to 10 million yuan in the first half of the year reversed the year-on-year loss
On July 13丨Shang Rong Medical (002551.SZ) announced the 2023 semi-annual results forecast. Net profit for the reporting period attributable to shareholders of listed companies was 8 million yuan to 10 million yuan, turning a loss into a profit from the previous year; net profit profit after deducting non-recurring profit and loss was 3.4787 million yuan to 5.4787 million yuan; basic earnings per share of 0.009 yuan/share - 0.012 yuan/share. Reasons for changes in performance: 1. In the reporting period, due to exchange rate fluctuations, which affected the company's exchange losses, decreased significantly year on year; 2. Due to the year-on-year decrease in loan amounts, it affected the company's interest expenses on the same period
Shenzhen Glory Medical Dismisses Claims of Staff Layoffs
Shenzhen Glory Medical (SHE:002551) refuted media reports regarding alleged staff layoffs and insufficient orders by the company. The Chinese medical device company said it has noted media reports fro
Shang Rong Medical (002551.SZ): The number of employees left in single digits is a false report
On June 29丨Shang Rong Medical (002551.SZ) issued a clarification notice. It recently paid attention to Times Finance and other media reports such as “The company is suspected to have insufficient orders, employees are on 'summer vacation', and there are only single digits left for employees working in the production division.” In order to avoid media reports from misleading investors, clarifications are now being made. After verification, it is true that some employees of the company's Shenzhen production division are on vacation due to the company's production capacity adjustments, but it is untrue that there are only single digits left on the job. The company explains the above media reports as follows: The company's Shenzhen production division provides the production of supporting products for the company's medical engineering business
No Data